Evaluation of the Efficacy and Safety of Griflow® Dual, a Pre-Set Two-Flow Infusion Device for Intravenous Immunoglobulin (Flebogamma® 5%) Administration

Author:

Sánchez Argentina1,Álvarez Magdalena1,Bustillo María Adoración1,García María Carmen1,Muñoz Margarita1,Pacios Concepción1,Pizarroso Lorena1,Rubio María Isabel1,Rodríguez Nuria2

Affiliation:

1. La Paz University Hospital, Madrid - Spain

2. Laboratorios Grifols S.A., Parets del Vallès, Barcelona - Spain

Abstract

Purpose A single center, prospective study was performed to assess the efficacy and safety of Griflow® Dual–-a gravity-fed device for intravenous delivery of human immunoglobulin Flebogamma®. Methods A total of 2 infusions in 2 visits per patient were assessed using G2 and G3 Griflow® Dual models that provide different flow rates adjusted to the patient's weight. To follow the most common method of intravenous immunoglobulin administration, infusion through the two-way device commenced with the low flow rate capillary (clamp closed) for 30 minutes and continued with the high flow rate, opening both ways. Reliability of flow delivery (average flow rates), adverse events, as well as functionality in daily practice (questionnaire to nurses) were assessed. Results twenty-five valid infusions were evaluated on 13 subjects. Except for the G2 model with closed clamp in which 14.5% deviation was observed, actual average flow rate values fell well into the maximum 10% deviation permitted with respect to expected charted values (G2: 55 and 142 mL/h; G3: 76 and 189 mL/h). Discrepancies could be explained by patient's arm movements or posture change during infusion. No adverse events related to the study device occurred. In the functionality questionnaires, nurse's comfort and safety of infusion with Griflow® Dual were rated higher than without Griflow® Dual but lower than with infusion pumps. Conclusions Although it may not be as precise as an infusion pump, Griflow® Dual proved to be a reliable and suitable device to administer Flebogamma® 5%. Correct safety should be confirmed in a larger sample.

Publisher

SAGE Publications

Subject

Nephrology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3